Replacement dehydroepiandrosterone in the elderly: Rationale and prospects for the future

被引：10

作者：

Casson, PR ^{[1
]}

Carson, SA ^{[1
]}

Buster, JE ^{[1
]}

机构：

[1] Baylor Coll Med, OBGYN, Houston, TX 77030 USA

来源：

ENDOCRINOLOGIST | 1998年 / 8卷 / 03期

关键词：

D O I：

10.1097/00019616-199805000-00010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Age related declines in dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate have been postulated to aggravate some diseases of aging. As a result, DHEA supplementation of ten is touted as the "fountain of youth," and it is being used widely in an unregulated fashion with out evidence of efficacy or safety. This review addresses DHEA replacement, discussing issues of bioavailability and possible beneficial effects. Safety concerns also are addressed. At present, we believe that DHEA replacement is not suitable for widespread clinical use; however, the potential for future hormonal therapy of aging using this compound is such that fur ther investigation certainly is warranted.

引用

页码：187 / 194

页数：8

共 30 条

[1]

Araneo B, 1995, ANN NY ACAD SCI, V774, P232

[2]

BARNHART KT, 1997, 53 ANN M AM SOC REPR

[3]

BARRETTCONNOR E, 1987, NEW ENGL J MED, V317, P711

[4] The epidemiology of DHEAS and cardiovascular disease [J].